Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.
Diana L ShusterRajeev M MenonBifeng DingAmit KhatriHong LiEric CohenMelissa JewettDaniel E CohenJiuhong ZhaPublished in: European journal of clinical pharmacology (2018)
Clinicaltrials.gov identifiers: NCT02207088 (RUBY-I) and NCT02487199 (RUBY-II).